Enhancement of Memory Retrieval and Attenuation of Scopolamine‐Induced Amnesia Following Administration of 5‐HT₃ Antagonist ICS 205‐930

Abstract

Experimental evidence suggests an important role of serotonin in the process of learning and memory. The present study investigated the effect of 5HT3-receptor antagonist (ICS 205-930) on retrieval of a previously learned aversive habit in the mouse. The effect of ICS 205-930 on scopolamine (3 mg/kg) induced amnesia was also studied. ICS 205-930 (1, 10 & 100 micrograms/kg) produced a dose-dependent increase in latency to cross into the dark chamber. The scopolamine induced memory impairment was significantly attenuated by ICS 205-930 (10 micrograms/kg). These results suggest that memory deficits may be susceptible to attenuation with non-cholinergic treatments.

Anticonvulsant Profile of Ondansetron in Rats

“…There are reports that 5HT 3 antagonists may attenuate scopolamine-induced deficits in passive avoidance learning (17,18). The mechanisms involved are unclear, but may involve facilitation of cholinergic transmission in brain following treatment with 5HT 3 receptor antagonists (19).…”

Enhanced delayed matching performance in younger and older macaques administered the 5-HT 4 receptor agonist, RS 17017

“…Ondansetron, a 5-HT 3 receptor antagonist, improves performance in several rodent and primate memory tasks while lacking cholinergic side effects (Barnes et al 1989a,b;Carey et al 1992;Fontana et al 1995). Other selective 5-HT 3 receptor antagonists, granisetron, tropisetron, and itasetron (DAU 6215) also improve memory in rodents (Chugh et al 1991a,b, Pitsikas et al 1994, and RS 56812 improves memory in monkeys (Terry et al 1996).…”

Structure Activity Relationship of Homochiral 7-Substituted 1-Aminoindans as 5-HT1A Receptor Ligands

“…T h e 5 -H T 3 antagonists tropisetron, granisetron, and ondansetron are efficacious drugs against anticancer drug induced vomiting [16,17] . Ondansetron is also evaluated in clinical trials for treatment of cognitive disorders [18][19][20] and schizophrenia [21,22] . Cisapride belongs to the 5-HT 4 agonists, and was one of the first marketed drugs against reduced gastric motility in this group, even though other properties are probably also involved [23][24][25][26] .…”